| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income including non-controlling interest | 48,830 | 31,188 |
| Depreciation and amortization | 17,756 | 11,924 |
| Provision for credit losses | 5,916 | 3,843 |
| Equity-based awards compensation expense | 6,151 | 3,888 |
| Amortization of debt issue costs | 315 | 210 |
| Change in deferred income taxes | 11,163 | 7,279 |
| Change in revaluation of put-right liability | -1,406 | -743 |
| Change in fair value of contingent earn-out consideration | 11,484 | 5,612 |
| Equity of earnings in unconsolidated affiliate | 1,155 | 794 |
| Loss on sale of fixed assets | -420 | -438 |
| Loss on sale of a partnership | -123 | -123 |
| Other | 0 | - |
| Patient accounts receivable, net | 13,604 | 10,232 |
| Accounts receivable - other | -3,559 | -355 |
| Other current and long term assets | 8,155 | 4,426 |
| Accounts payable and accrued expenses | -10,908 | -7,914 |
| Other long-term liabilities | -207 | -827 |
| Net cash provided by operating activities | 50,126 | 30,186 |
| Purchase of fixed assets | 10,145 | 5,830 |
| Purchase of interest in businesses, net of cash acquired | 15,214 | 6,890 |
| Purchase of redeemable non-controlling interest, temporary equity | 8,579 | 8,427 |
| Repayment of notes receivable related to redeemable non-controlling interest | - | 346 |
| Purchase of non controlling interest, permanent equity | 196 | 149 |
| Proceeds from the sale of non-controlling interest, permanent equity | 9 | 9 |
| Proceeds from the sale of partnership interest - redeemable non-controlling interest, temporary equity | 149 | 15 |
| Repayment of notes receivable related to sales of redeemable non-controlling interest | 387 | - |
| Proceeds from the sale of partnership | 700 | 700 |
| Distributions from unconsolidated affiliate | 1,089 | 664 |
| Other | -531 | -228 |
| Net cash (used in) investing activities | -31,269 | -19,334 |
| Proceeds from revolving facility | 146,500 | 73,500 |
| Payments on revolving facility | 131,000 | 60,000 |
| Distributions to non-controlling interest, permanent and temporary equity | 14,610 | 10,697 |
| Cash dividends paid to shareholders | 20,520 | 13,678 |
| Payments on term loan | 7,500 | 5,625 |
| Principal payments on notes payable | 1,994 | 1,628 |
| Other | 7 | - |
| Net cash (used in) financing activities | -29,117 | -18,128 |
| Net (decrease) in cash and cash equivalents | -10,260 | -7,276 |
| Cash and cash equivalents at beginning of period | 41,362 | - |
| Cash and cash equivalents at end of period | 31,102 | - |
U S PHYSICAL THERAPY INC NV (USPH)
U S PHYSICAL THERAPY INC NV (USPH)